MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes): Disease Characteristics Research Report

Executive summary

MELAS syndrome is a maternally inherited mitochondrial disorder, classically defined by mitochondrial encephalopathy, lactic acidosis, and recurrent stroke-like episodes (SLEs). It is most commonly caused by heteroplasmic mtDNA variants affecting mitochondrial tRNA genes, especially MT-TL1 m.3243A>G (~80% of cases in multiple contemporary reviews/cohorts). Clinical presentation is multisystemic, but neurologic manifestations (SLEs, seizures, cognitive decline) dominate morbidity and mortality. Recent population-based epidemiology (2024) and large “clinically unselected” genomics (2024) have refined prevalence/incidence and penetrance estimates, supporting genotype/heteroplasmy-stratified risk assessment. Therapeutics remain largely supportive; the strongest interventional evidence in MELAS-specific SLE prevention includes high-dose taurine (open-label phase III trial) and systematic L-arginine regimens (prospective multicenter), with ongoing clinical trials targeting redox/bioenergetics.

1. Disease information

1.1 What is the disease? (overview and definition)

MELAS is a rare mitochondrial syndrome characterized by encephalopathy, lactic acidosis, and stroke-like episodes (SLEs) with non-vascular-distribution brain lesions that may shift over time. Reviews emphasize its broad systemic manifestations (neurologic, muscular, endocrine, cardiac, renal), but recurrent SLEs and seizures are key clinical drivers of disability. (na2024diagnosisandmanagement pages 1-2, na2024diagnosisandmanagement pages 8-9)

Abstract-quotable definition (recent cohort/review): - Xu et al. (Orphanet J Rare Dis, 2024-12, DOI: 10.1186/s13023-024-03511-4) describes MELAS as “Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes,” a maternally inherited mitochondrial disorder affecting primarily the CNS and skeletal muscle. (xu2024multisystemclinicopathologicand pages 1-2)

1.2 Key identifiers

Available in retrieved evidence - OMIM: #540000 (explicitly stated in Xu et al. 2024). (xu2024multisystemclinicopathologicand pages 1-2)

Not found in retrieved evidence (should be confirmed from external disease ontologies/databases): - Orphanet (ORPHA), ICD-10/ICD-11, MeSH, MONDO.

1.3 Synonyms and alternative names

• “Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes” (expansion of MELAS) (na2024diagnosisandmanagement pages 1-2)
• “Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes” (common spelling variant) (ohsawa2019taurinesupplementationfor pages 1-2)

1.4 Evidence provenance (individual patients vs disease resources)

Evidence used here is derived from: - Aggregated disease-level resources: narrative reviews (e.g., Na & Lee 2024). (na2024diagnosisandmanagement pages 1-2) - Human clinical cohorts/registries: imaging cohorts (Zheng 2023), multisystem retrospective cohorts (Xu 2024; Cox 2023), and population-based epidemiology (Martikainen 2024). (zheng2023mitochondrialencephalomyopathywith pages 1-2, xu2024multisystemclinicopathologicand pages 1-2, cox2023theclinicalspectrum pages 1-2, martikainen2024incidenceandprevalence pages 1-2) - Interventional clinical trials: taurine phase III open-label trial; idebenone randomized trial; ClinicalTrials.gov interventional studies. (ohsawa2019taurinesupplementationfor pages 1-2, NCT00887562 chunk 1)

2. Etiology

2.1 Disease causal factors

Genetic (primary): MELAS is most commonly due to pathogenic mtDNA variants affecting mitochondrial translation, especially heteroplasmic MT-TL1 m.3243A>G, repeatedly cited as accounting for ~80% of MELAS cases. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

Other mtDNA variants associated with MELAS include MT-ND5 (e.g., m.13513G>A, ~10–15% in one 2024 review) and other tRNA gene variants (e.g., MT-TH, MT-TK), plus rarer MT-TL1 variants (e.g., m.3271T>C). (na2024diagnosisandmanagement pages 7-8)

Mechanistic causal chain (current understanding): - Pathogenic mtDNA variants impair mitochondrial protein synthesis → defective oxidative phosphorylation (OXPHOS) → cellular energy failure and lactate accumulation. (na2024diagnosisandmanagement pages 7-8) - Stroke-like episodes are non-vascular and are hypothesized to involve multiple interacting mechanisms including mitochondrial angiopathy/vasculopathy, mitochondrial cytopathy, and neuronal excitotoxicity. (zheng2023mitochondrialencephalomyopathywith pages 1-2, xu2024multisystemclinicopathologicand pages 1-2)

2.2 Risk factors

Genetic risk factors - Presence of heteroplasmic pathogenic mtDNA variants, especially m.3243A>G, with higher heteroplasmy generally associated with greater multisystem risk. - In UK Biobank WGS, multi-system disease risk and penetrance for diabetes/deafness/heart failure increased substantially when m.3243A>G heteroplasmy reached ≥10% (see Section 9). (cannon2024penetranceandexpressivity pages 1-2)

Environmental/physiologic risk factors (evidence-limited in retrieved texts): - Episodes may be precipitated by physiologic stressors (infections, metabolic decompensation), but specific quantified environmental triggers were not systematically captured in the retrieved evidence.

2.3 Protective factors

No validated genetic “protective variants” were identified in the retrieved evidence. Nonetheless, Cannon et al. suggests that penetrance of most pathogenic mtDNA variants is low in unselected populations (exception m.3243A>G at higher heteroplasmy), implying that host genetic background (including polygenic risk) can modify expression. (cannon2024penetranceandexpressivity pages 1-2)

2.4 Gene–environment / gene–gene interactions

Cannon et al. (Human Mol Genet, 2024-11, DOI: 10.1093/hmg/ddad194) reports that diabetes risk with m.3243A>G was further influenced by type 2 diabetes genetic risk, supporting gene–gene interaction between mtDNA heteroplasmy and nuclear polygenic susceptibility. (cannon2024penetranceandexpressivity pages 1-2)

3. Phenotypes

3.1 Core phenotype spectrum (with frequencies where available)

A concise frequency summary (from a phenotype-focused review letter) reports: - SLEs: >90% - Seizures: 76% - Headache: 50% - Vomiting: 55% - Visual loss: 52% - Muscle weakness: 48% - Short stature: >25% - Diabetes: 10–24% These estimates should be interpreted cautiously because they are compiled narrative frequencies rather than from a single prospective cohort. (finsterer2020rarephenotypicmanifestations pages 1-2)

A 2023 large retrospective cohort spanning MELAS to asymptomatic carriers reported: - Seizures in MELAS: 88.1% (vs 16.7% in symptomatic non-MELAS). (cox2023theclinicalspectrum pages 1-2) - Late-onset MELAS had high diabetes (69.2%) and nephropathy (53.8%), suggesting phenotype shifts with age at first SLE. (cox2023theclinicalspectrum pages 1-2)

3.2 Phenotype characteristics (onset, severity, progression)

• SLEs are typically before age 40 in classic MELAS definitions; location of lesions can shift over time and does not respect vascular territories. (na2024diagnosisandmanagement pages 7-8, na2024diagnosisandmanagement pages 8-9)
• Disease course is progressive with recurrent neurological events contributing to reduced life expectancy. (na2024diagnosisandmanagement pages 1-2)

3.3 Quality-of-life impact

Quantitative QoL instruments (e.g., SF-36, EQ-5D, PROMIS) were not reported in the retrieved evidence. Functional outcomes, however, were captured via modified Rankin Scale (mRS) distributions in a 2024 cohort (Section 11). (gao2024longtermprognosticfactors pages 1-2)

3.4 Suggested HPO terms

A phenotype-to-HPO mapping table is provided below.

Table: This table maps core MELAS manifestations to suggested Human Phenotype Ontology terms and summarizes frequency or onset information from the retrieved evidence. It is useful for structured phenotype curation in a disease knowledge base.

4. Genetic / molecular information

4.1 Causal genes

Primary causal locus (mtDNA): - MT-TL1 (mitochondrially encoded tRNA leucine 1) with canonical m.3243A>G heteroplasmic variant. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

Other mtDNA genes/regions implicated (not exhaustive; examples from retrieved evidence): - MT-ND5 (including m.13513G>A), MT-TH, MT-TK, and other tRNA genes; additional variants reported in one 2024 cohort include m.5628T>C, m.6352-13952del, and 9-bp deletions combined with m.3243A>G. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

4.2 Pathogenic variants and heteroplasmy

• m.3243A>G is typically heteroplasmic, and clinical severity varies with tissue mutation load (threshold effect) and tissue distribution; one 2024 review summarizes that higher mutant load is often found in muscle/urine than blood. (na2024diagnosisandmanagement pages 7-8)
• In a large clinically unselected cohort, higher m.3243A>G heteroplasmy (≥10%) was associated with markedly increased odds of diabetes, deafness, and heart failure. (cannon2024penetranceandexpressivity pages 1-2)

4.3 Modifier genes / nuclear factors

Direct nuclear “modifier genes” were not extracted from the retrieved texts. However, polygenic type 2 diabetes genetic risk modified diabetes risk in m.3243A>G carriers. (cannon2024penetranceandexpressivity pages 1-2)

4.4 Epigenetic and chromosomal abnormalities

No MELAS-specific epigenetic or chromosomal abnormality evidence was found in the retrieved texts.

5. Environmental information

Specific toxins, lifestyle exposures, or infectious triggers were not systematically quantified in the retrieved evidence. Physiological stressors are commonly discussed in case reports and reviews but are outside the evidence captured here.

6. Mechanism / pathophysiology

6.1 Molecular pathways and cellular processes

Upstream driver: impaired mitochondrial translation and OXPHOS defect → ATP deficit and lactate accumulation (systemic and cerebral). (na2024diagnosisandmanagement pages 7-8)

Stroke-like episode mechanisms (multiple interacting hypotheses): - Mitochondrial vasculopathy/angiopathy: microvascular dysfunction and impaired perfusion; NO deficiency is a prominent mechanistic hypothesis supporting arginine/citrulline therapy. (xu2024multisystemclinicopathologicand pages 1-2, elhattab2017arginineandcitrulline pages 1-2) - Mitochondrial cytopathy: direct neuronal/glial energy failure. (zheng2023mitochondrialencephalomyopathywith pages 1-2) - Neuronal excitotoxicity / hyperexcitability: implicated by seizure association and some imaging/clinical patterns. (zheng2023mitochondrialencephalomyopathywith pages 1-2)

6.2 Metabolic changes and biochemical abnormalities

Lactic acidosis and MRS lactate: - Proton MRS commonly shows elevated lactate peaks; e.g., in an m.3243A>G imaging cohort, lactate peaks were present in 9/10 (90%) measured cases. (zheng2023mitochondrialencephalomyopathywith pages 1-2)

31P-MRS (energetics signature): - A 2024 multisystem cohort reports abnormal Pi/PCr ratios on 31P-MRS, consistent with disturbed high-energy phosphate metabolism. (xu2024multisystemclinicopathologicand pages 1-2)

6.3 “Omics” and molecular profiling

No transcriptomic/proteomic/metabolomic multi-omics datasets specific to MELAS were retrieved here. Metabolic profiling proxies available include 1H-MRS and 31P-MRS energetics measures. (xu2024multisystemclinicopathologicand pages 1-2, zheng2023mitochondrialencephalomyopathywith pages 1-2)

6.4 Suggested ontology terms for mechanisms

GO Biological Process (suggestions; ontology IDs should be confirmed against GO): - Mitochondrial translation; oxidative phosphorylation; ATP metabolic process; response to oxidative stress; regulation of cerebral blood flow; excitatory synaptic transmission.

Cell Ontology (CL) cell types implicated (suggestions): - Cerebral vascular endothelial cell; neuron; astrocyte; skeletal muscle fiber.

7. Anatomical structures affected

7.1 Organ/system level

Commonly involved systems include: - Central nervous system (stroke-like lesions, seizures, progressive decline). (na2024diagnosisandmanagement pages 1-2) - Skeletal muscle (myopathy, weakness, exercise intolerance). (na2024diagnosisandmanagement pages 1-2, xu2024multisystemclinicopathologicand pages 1-2) - Endocrine/metabolic (diabetes). (na2024diagnosisandmanagement pages 1-2, cox2023theclinicalspectrum pages 1-2) - Cardiac (hypertrophic cardiomyopathy/arrhythmias noted in reviews; heart failure association in population genomics). (na2024diagnosisandmanagement pages 8-9, cannon2024penetranceandexpressivity pages 1-2) - Renal (nephropathy in late-onset phenotype). (cox2023theclinicalspectrum pages 1-2)

7.2 Tissue/cell and subcellular level

• Mitochondria (subcellular compartment) are central; muscle biopsy may show ragged red fibers and COX-defective fibers indicating mitochondrial proliferation and respiratory chain dysfunction. (xu2024multisystemclinicopathologicand pages 1-2, na2024diagnosisandmanagement pages 8-9)

7.3 Neuroanatomical localization patterns (quantitative imaging)

A 2023 imaging analysis of m.3243A>G MELAS reported predominant posterior cortical involvement: - Occipital: 63% (37/59) - Parietal: 54% (32/59) - Temporal: 51% (30/59) with frequent atrophy and lesion polymorphism; see quantitative table below. (zheng2023mitochondrialencephalomyopathywith pages 1-2)

8. Temporal development

8.1 Onset

• Classic MELAS definitions emphasize early-onset stroke-like episodes (often before age 40). (elhattab2017arginineandcitrulline pages 1-2, na2024diagnosisandmanagement pages 7-8)
• A 2023 cohort distinguished “standard-onset” (first SLE <40) versus late-onset; late-onset cases had longer prodromal periods and died later (mean age at death 62 vs 30). (cox2023theclinicalspectrum pages 1-2)

8.2 Progression and course

• Disease course is typically progressive with episodic neurologic decompensation (SLEs, status epilepticus) and accumulating deficits. (na2024diagnosisandmanagement pages 1-2, gao2024longtermprognosticfactors pages 1-2)

9. Inheritance and population

9.1 Inheritance

• Mitochondrial (maternal) inheritance is a defining property; heteroplasmy and tissue distribution create variable expressivity and incomplete penetrance. (na2024diagnosisandmanagement pages 7-8, xu2024multisystemclinicopathologicand pages 1-2)

9.2 Epidemiology (recent data prioritized)

A 2024 observational population-based study in Southwest Finland reported adult mtDNA disease epidemiology that can serve as a modern benchmark (not MELAS-specific only, but includes m.3243A>G-related disease): - Adult mtDNA disease prevalence (2022): 9.2/100,000 (95% CI 6.5–12.7). (martikainen2024incidenceandprevalence pages 1-2) - Adult m.3243A>G-related disease prevalence: 4.2/100,000 (95% CI 2.5–6.7). (martikainen2024incidenceandprevalence pages 1-2) - Annual incidence (2010–2022): adult mtDNA disease 0.6/100,000; adult m.3243A>G-related disease 0.3/100,000. (martikainen2024incidenceandprevalence pages 1-2) The authors explicitly note that improved diagnostics and dedicated ascertainment increase detection, and that under-recognition of oligosymptomatic cases is likely. (martikainen2024incidenceandprevalence pages 2-3, martikainen2024incidenceandprevalence pages 3-4)

9.3 Penetrance and expressivity (2024 large unselected cohort)

In UK Biobank WGS, Cannon et al. showed: - Most pathogenic mtDNA variants had low penetrance in unselected populations, except m.3243A>G. (cannon2024penetranceandexpressivity pages 1-2) - When m.3243A>G heteroplasmy ≥10%, odds ratios increased markedly: - Diabetes OR: 5.61 → 25.1 - Deafness OR: 12.3 → 55.0 - Heart failure OR: 10.1 → 39.5 This supports quantitative heteroplasmy thresholds for clinical risk stratification and incidental reporting discussions. (cannon2024penetranceandexpressivity pages 1-2)

10. Diagnostics

10.1 Clinical and biochemical tests

Common diagnostic elements include: - Lactic acidosis (plasma and/or CSF lactate/pyruvate) and lactate peaks on MRS. (na2024diagnosisandmanagement pages 8-9) - Neuroimaging: cortical/subcortical lesions not respecting vascular territories; lesions may shift over time. (na2024diagnosisandmanagement pages 8-9) - Muscle biopsy (when genetic testing inconclusive): ragged red fibers (RRF) and COX-defective fibers may support diagnosis. (xu2024multisystemclinicopathologicand pages 1-2)

10.2 Genetic testing

• Genetic diagnosis commonly relies on mtDNA testing to identify causative variants and measure heteroplasmy. A 2024 review notes tissue heteroplasmy differences (muscle/urine often higher than blood), implying that multi-tissue testing improves sensitivity. (na2024diagnosisandmanagement pages 7-8)

10.3 Clinicoradiologic criteria for stroke-like episodes (SLE) (real-world implementation)

Stroke-like episodes are frequently misdiagnosed as acute ischemic stroke. A 2023 Neurology Genetics study derived and validated pragmatic criteria and an algorithm using clinical history and CT/CTA patterns: - “Possible SLE” criteria: sensitivity 100%, specificity 81% (AUC 0.905). - “Probable SLE” criteria: sensitivity 88%, specificity 95% (AUC 0.917). (khasminsky2023clinicoradiologiccriteriafor pages 1-2)

Visual evidence (Table and diagnostic algorithm): (khasminsky2023clinicoradiologiccriteriafor media eef69170, khasminsky2023clinicoradiologiccriteriafor media 6adc2877)

11. Outcome / prognosis

11.1 Survival and mortality (cohort evidence)

• In one 2023 retrospective spectrum cohort, MELAS showed 50% mortality at 25 years from onset (comparison group 10%). (cox2023theclinicalspectrum pages 1-2)

11.2 Functional outcomes and prognostic markers (2024 cohort)

A 2024 retrospective cohort (n=39; mean follow-up 7.3±4.7 years) reported: - Deaths: 8/39, primarily due to acute SLEs and status epilepticus. (gao2024longtermprognosticfactors pages 1-2) - mRS distribution: 41% (0–2), 38.5% (3–5), 20.5% (6 or died). (gao2024longtermprognosticfactors pages 1-2) - Independent mortality predictors: - Severe lactate elevation OR 7.279 (95% CI 1.102–48.086) - Anemia associated with poor prognosis (reported OR 0.137 with CI 0.021–0.908; directionality in the paper indicates anemia as an adverse prognostic factor). (gao2024longtermprognosticfactors pages 1-2)

12. Treatment

12.1 Current standard of care (supportive)

A 2024 management review describes MELAS care as largely supportive, including anti-seizure medications, metabolic supplementation (arginine/citrulline, high-dose taurine), and dietary therapies. (na2024diagnosisandmanagement pages 1-2)

A practical dosing example from the same review for commonly used mitochondrial cofactors includes: - CoQ10: “typically” 30 mg/kg/day - Riboflavin: 50–400 mg daily - L-carnitine: 50–100 mg/kg/day These are supportive and not disease-modifying for the mtDNA defect. (na2024diagnosisandmanagement pages 8-9)

MAXO (treatment action) suggestions (confirm in MAXO): - Intravenous amino acid supplementation (L-arginine) - Oral amino acid supplementation (L-arginine; L-citrulline) - Taurine supplementation - Antiseizure therapy - Nutritional therapy / dietary intervention

12.2 Targeted symptomatic/preventive therapies for SLEs

Taurine (high-dose oral)

A multicenter open-label phase III trial in 10 patients with recurrent SLEs administered 9 g/day or 12 g/day taurine for 52 weeks: - Primary endpoint (complete prevention): 60% (95% CI 26.2–87.8) - ≥50% reduction responder rate: 80% (95% CI 44.4–97.5) - Annual relapse rate reduced 2.22 → 0.72 (P=0.001) - No severe adverse events attributed to taurine. (ohsawa2019taurinesupplementationfor pages 1-2) Mechanistically, the trial frames MELAS as a “tRNA modification disorder” in which taurine corrects defective taurine modification of mitochondrial tRNALeu(UUR), improving decoding fidelity. (ohsawa2019taurinesupplementationfor pages 1-2)

L-arginine (acute and prophylactic regimens)

A 9-year prospective multicenter Japanese clinical research program tested systematic oral and IV L-arginine: - Oral: 0.3–0.5 g/kg/day for 2 years - IV: 0.5 g/kg per dose (acute ictus regimen) - Observed benefits included decreased incidence/severity of ictuses and improvement in acute symptoms (headache, nausea/vomiting, impaired consciousness, visual disturbance) with favorable tolerability. (koga2018therapeuticregimenof pages 1-2) A 2022 systematic review synthesizing small trials reported decreases in stroke-like episode frequency and severity scores with oral prophylaxis, and symptomatic improvements with IV arginine. (argudo2022arginineforthe pages 4-5)

Citrulline

Citrulline is discussed as a nitric oxide precursor potentially increasing NO production more robustly than arginine; however, clinical efficacy studies were noted as limited in older reviews. (elhattab2017arginineandcitrulline pages 1-2)

12.3 Experimental / emerging therapies (pipeline)

A 2024 review describes experimental directions such as gene therapy and mitochondrial replacement techniques, along with redox/mitochondrial-targeted candidates. (na2024diagnosisandmanagement pages 1-2, na2024diagnosisandmanagement pages 12-14)

13. Prevention

Primary prevention of MELAS itself is genetic (maternal transmission risk reduction). The retrieved evidence mentions mitochondrial replacement therapy conceptually as a preventive reproductive strategy (without clinical outcome data in the retrieved excerpts). (na2024diagnosisandmanagement pages 12-14)

Secondary/tertiary prevention focuses on preventing or mitigating SLEs and seizures: - Taurine prophylaxis and arginine/citrulline strategies are used to reduce SLE frequency/severity. (ohsawa2019taurinesupplementationfor pages 1-2, koga2018therapeuticregimenof pages 1-2)

14. Other species / natural disease

No naturally occurring MELAS analogs in non-human species were identified in the retrieved evidence.

15. Model organisms

No animal or cellular model organism resources were identified in the retrieved evidence.

Quantitative evidence summary table

Table: This table compiles key quantitative findings on MELAS syndrome from recent and landmark studies, including genetics, imaging, prognosis, phenotype burden, treatment outcomes, and population epidemiology. It is useful as a compact evidence summary for knowledge base curation and report drafting.

Real-world implementations and clinical trials (selected)

Recent and active clinical research is visible in ClinicalTrials.gov records: - NCT01339494 (completed; Early Phase 1; n=30): oral L-arginine and L-citrulline (10 g/m²/day divided q4h for 48 h each) with primary outcome change in nitric oxide production; includes patients with m.3243A>G. (NCT01339494 chunk 1) - NCT03952234 (completed; Phase 1; n=10): L-citrulline dose-finding in adults with MELAS and m.3243A>G; primary outcome maximum tolerable dose / DLTs over 8 weeks. (NCT03952234 chunk 1) - NCT00887562 (completed; Phase IIa; randomized, placebo-controlled; n=27): idebenone 900 or 2250 mg/day for 1 month; primary outcome change in cerebral lactate by MRS. (NCT00887562 chunk 1) - NCT06644534 (recruiting; Phase 2; planned n=12): TTI-0102 (cysteamine-pantetheine disulfide) vs placebo; primary outcomes include 12-minute walk test change and safety; inclusion requires MELAS-associated mtDNA variants with heteroplasmy thresholds and clinical features including stroke-like episodes. (NCT06644534 chunk 1)

Limitations of this evidence package (important for knowledge base curation)

• PMIDs were not present in the retrieved excerpts for many sources; therefore, PMID-level citation could not be systematically provided despite the user preference. DOIs/URLs and publication dates are provided whenever available in the retrieved evidence.
• Orphanet/ICD/MeSH/MONDO codes were not explicitly captured in the retrieved texts, except OMIM #540000 from Xu 2024; these should be supplemented by direct lookup in OMIM/Orphanet/MONDO/MeSH.
• Multi-omics (transcriptomics/proteomics/metabolomics) MELAS datasets were not retrieved in this run; only MRS-based metabolic profiling proxies were available.

References

1. (na2024diagnosisandmanagement pages 1-2): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.

2. (na2024diagnosisandmanagement pages 8-9): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.

3. (xu2024multisystemclinicopathologicand pages 1-2): Shuai Xu, Jialiu Jiang, Leilei Chang, Biao Zhang, Xiaolei Zhu, and Fengnan Niu. Multisystem clinicopathologic and genetic analysis of melas. Orphanet Journal of Rare Diseases, Dec 2024. URL: https://doi.org/10.1186/s13023-024-03511-4, doi:10.1186/s13023-024-03511-4. This article has 8 citations and is from a peer-reviewed journal.

4. (ohsawa2019taurinesupplementationfor pages 1-2): Yutaka Ohsawa, Hiroki Hagiwara, Shin-ichiro Nishimatsu, Akihiro Hirakawa, Naomi Kamimura, Hideaki Ohtsubo, Yuta Fukai, Tatsufumi Murakami, Yasutoshi Koga, Yu-ichi Goto, Shigeo Ohta, and Yoshihide Sunada. Taurine supplementation for prevention of stroke-like episodes in melas: a multicentre, open-label, 52-week phase iii trial. Journal of Neurology, Neurosurgery, and Psychiatry, 90:529-536, Apr 2019. URL: https://doi.org/10.1136/jnnp-2018-317964, doi:10.1136/jnnp-2018-317964. This article has 171 citations.

5. (zheng2023mitochondrialencephalomyopathywith pages 1-2): Helin Zheng, Xuemei Zhang, Lu Tian, Bo Liu, Xiaoya He, Longlun Wang, Shuang Ding, Yi Guo, and Jinhua Cai. Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes with an mt-tl1 m.3243a>g point mutation: neuroradiological features and their implications for underlying pathogenesis. Frontiers in Neuroscience, Jan 2023. URL: https://doi.org/10.3389/fnins.2022.1028762, doi:10.3389/fnins.2022.1028762. This article has 14 citations and is from a peer-reviewed journal.

6. (cox2023theclinicalspectrum pages 1-2): Benjamin C. Cox, Jennifer Y. Pearson, Jay Mandrekar, and Ralitza H. Gavrilova. The clinical spectrum of melas and associated disorders across ages: a retrospective cohort study. Frontiers in Neurology, Dec 2023. URL: https://doi.org/10.3389/fneur.2023.1298569, doi:10.3389/fneur.2023.1298569. This article has 17 citations and is from a peer-reviewed journal.

7. (martikainen2024incidenceandprevalence pages 1-2): Mika H Martikainen and Kari Majamaa. Incidence and prevalence of mtdna-related adult mitochondrial disease in southwest finland, 2009–2022: an observational, population-based study. BMJ Neurology Open, 6:e000546, Feb 2024. URL: https://doi.org/10.1136/bmjno-2023-000546, doi:10.1136/bmjno-2023-000546. This article has 9 citations and is from a peer-reviewed journal.

8. (NCT00887562 chunk 1): Michio Hirano. Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes. Michio Hirano. 2009. ClinicalTrials.gov Identifier: NCT00887562

9. (na2024diagnosisandmanagement pages 7-8): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.

10. (cannon2024penetranceandexpressivity pages 1-2): Stuart J Cannon, Timothy Hall, Gareth Hawkes, Kevin Colclough, Roisin M Boggan, Caroline F Wright, Sarah J Pickett, Andrew T Hattersley, Michael N Weedon, and Kashyap A Patel. Penetrance and expressivity of mitochondrial variants in a large clinically unselected population. Human Molecular Genetics, 33:465-474, Nov 2024. URL: https://doi.org/10.1093/hmg/ddad194, doi:10.1093/hmg/ddad194. This article has 15 citations and is from a domain leading peer-reviewed journal.

11. (finsterer2020rarephenotypicmanifestations pages 1-2): Josef Finsterer. Rare phenotypic manifestations of melas. Yonsei Medical Journal, 61:904-906, Sep 2020. URL: https://doi.org/10.3349/ymj.2020.61.10.904, doi:10.3349/ymj.2020.61.10.904. This article has 5 citations and is from a peer-reviewed journal.

12. (gao2024longtermprognosticfactors pages 1-2): Rui Gao, Lihua Gu, Wenchao Zuo, and Pan Wang. Long-term prognostic factors and outcomes in mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes: a clinical and biochemical marker analysis. Frontiers in Neurology, Dec 2024. URL: https://doi.org/10.3389/fneur.2024.1491283, doi:10.3389/fneur.2024.1491283. This article has 7 citations and is from a peer-reviewed journal.

13. (elhattab2017arginineandcitrulline pages 1-2): Ayman W. El-Hattab, Mohammed Almannai, and Fernando Scaglia. Arginine and citrulline for the treatment of melas syndrome. Journal of inborn errors of metabolism and screening, 5:232640981769739, Mar 2017. URL: https://doi.org/10.1177/2326409817697399, doi:10.1177/2326409817697399. This article has 79 citations.

14. (khasminsky2023clinicoradiologiccriteriafor pages 1-2): Vadim Khasminsky, Eitan Auriel, Judith Luckman, Ruth Eliahou, Edna Inbar, Keshet Pardo, Yuval Landau, Rani Barnea, Maor Mermelstein, Shahar Shelly, Jonathan Naftali, and Shlomi Peretz. Clinicoradiologic criteria for the diagnosis of stroke-like episodes in melas. Aug 2023. URL: https://doi.org/10.1212/nxg.0000000000200082, doi:10.1212/nxg.0000000000200082. This article has 10 citations.

15. (martikainen2024incidenceandprevalence pages 2-3): Mika H Martikainen and Kari Majamaa. Incidence and prevalence of mtdna-related adult mitochondrial disease in southwest finland, 2009–2022: an observational, population-based study. BMJ Neurology Open, 6:e000546, Feb 2024. URL: https://doi.org/10.1136/bmjno-2023-000546, doi:10.1136/bmjno-2023-000546. This article has 9 citations and is from a peer-reviewed journal.

16. (martikainen2024incidenceandprevalence pages 3-4): Mika H Martikainen and Kari Majamaa. Incidence and prevalence of mtdna-related adult mitochondrial disease in southwest finland, 2009–2022: an observational, population-based study. BMJ Neurology Open, 6:e000546, Feb 2024. URL: https://doi.org/10.1136/bmjno-2023-000546, doi:10.1136/bmjno-2023-000546. This article has 9 citations and is from a peer-reviewed journal.

17. (khasminsky2023clinicoradiologiccriteriafor media eef69170): Vadim Khasminsky, Eitan Auriel, Judith Luckman, Ruth Eliahou, Edna Inbar, Keshet Pardo, Yuval Landau, Rani Barnea, Maor Mermelstein, Shahar Shelly, Jonathan Naftali, and Shlomi Peretz. Clinicoradiologic criteria for the diagnosis of stroke-like episodes in melas. Aug 2023. URL: https://doi.org/10.1212/nxg.0000000000200082, doi:10.1212/nxg.0000000000200082. This article has 10 citations.

18. (khasminsky2023clinicoradiologiccriteriafor media 6adc2877): Vadim Khasminsky, Eitan Auriel, Judith Luckman, Ruth Eliahou, Edna Inbar, Keshet Pardo, Yuval Landau, Rani Barnea, Maor Mermelstein, Shahar Shelly, Jonathan Naftali, and Shlomi Peretz. Clinicoradiologic criteria for the diagnosis of stroke-like episodes in melas. Aug 2023. URL: https://doi.org/10.1212/nxg.0000000000200082, doi:10.1212/nxg.0000000000200082. This article has 10 citations.

19. (koga2018therapeuticregimenof pages 1-2): Yasutoshi Koga, Nataliya Povalko, Eisuke Inoue, Hidefumi Nakamura, Akiko Ishii, Yasuhiro Suzuki, Makoto Yoneda, Fumio Kanda, Masaya Kubota, Hisashi Okada, and Katsunori Fujii. Therapeutic regimen of l-arginine for melas: 9-year, prospective, multicenter, clinical research. Journal of Neurology, 265:2861-2874, Sep 2018. URL: https://doi.org/10.1007/s00415-018-9057-7, doi:10.1007/s00415-018-9057-7. This article has 108 citations and is from a domain leading peer-reviewed journal.

20. (argudo2022arginineforthe pages 4-5): Jennifer M Argudo, Olga M Astudillo Moncayo, Walter Insuasti, Gabriela Garofalo, Alex S Aguirre, Sebastian Encalada, Jose Villamarin, Sebastian Oña, Maria Gabriela Tenemaza, Ahmed Eissa-Garcés, Sakina Matcheswalla, and Juan Fernando Ortiz. Arginine for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes: a systematic review. Cureus, Dec 2022. URL: https://doi.org/10.7759/cureus.32709, doi:10.7759/cureus.32709. This article has 23 citations.

21. (na2024diagnosisandmanagement pages 12-14): Ji-Hoon Na and Young-Mock Lee. Diagnosis and management of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. Biomolecules, 14:1524, Nov 2024. URL: https://doi.org/10.3390/biom14121524, doi:10.3390/biom14121524. This article has 29 citations.

22. (NCT01339494 chunk 1): Fernando Scaglia. Nitric Oxide Production in MELAS Syndrome. Baylor College of Medicine. 2009. ClinicalTrials.gov Identifier: NCT01339494

23. (NCT03952234 chunk 1): Fernando Scaglia. L-Citrulline Dose Finding Safety Study in MELAS. Baylor College of Medicine. 2021. ClinicalTrials.gov Identifier: NCT03952234

24. (NCT06644534 chunk 1): A Study to Assess TTI-0102 vs Placebo in MELAS Patients. Thiogenesis Therapeutics, Inc.. 2025. ClinicalTrials.gov Identifier: NCT06644534

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01